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Of 41 HIV-infected patients with facial lipoatrophy who un-
derwent autologous fat transplantation, disfiguring facial li-
pohypertrophy at the graft site occurred at the same time as
recurrent fat accumulation at the tissue harvest site in 4
patients who had had fat transferred from the dorsocervical
fat pad or from subcutaneous abdominal tissue.
Lipodystrophy associated with HAART includes subcutaneous
fat loss (i.e., lipoatrophy) in the face, limbs, or buttocks and/
or fat accumulation (i.e., lipohypertrophy) in the abdomen, in
the breast, and/or on the dorsocervical spine (resulting in a
dorsocervical fat pad or “buffalo hump”) [1]. In patients with
lipodystrophy, switching from treatment with either of the thy-
midine nucleoside analogues, stavudine or zidovudine, to treat-
ment with the nonthymidine analogue abacavir resulted in a
mild increase in peripheral fat mass; however, facial lipoatrophy
did not improve [2]. The only currently available clinical in-
terventions to treat facial lipoatrophy are fat transplantion sur-
gery or injection with inert colloidal preparations.
Patients and methods. At our Metabolic Clinic in Modena,
Italy, 41 HIV-infected patients with facial lipoatrophy under-
went autologous fat transplantation to treat facial-fat wasting
[3, 4]. Surgery was performed using the technique described
by Coleman [3]. Intact fat-tissue parcels were harvested, and
the nonviable components were removed; mechanical trauma,
exposure to infectious agents, and direct contact with air were
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avoided to allow the graft to remain metabolically active. The
graft was implanted with small cannulae in the subcutaneous
space to allow nutrition and cell anchoring. The source of the
graft was the subcutaneous abdominal region in 27 patients,
the dorsocervical fat pad in 14 patients, the breast in 2 patients,
and the pubis region in 2 patients. Few patients had multiple
harvest sites as the graft source.
Results. Of the 41 patients, 32.1% were women, and 21%
had Centers for Disease Control and Prevention (CDC) stage
C HIV disease. At baseline, the mean values (SD) for clinical
characteristics and laboratory values were as follows: age,
years; nadir CD4 cell count, cells/mL; dura-43 6 191 151
tion of exposure to HAART, months; and duration of65 17
exposure to stavudine, months. At the time of surgery,44 19
the patients’ mean (SD) CD4 cell count was cells/582 248
mL, and the median HIV load was copies/mL.9621 24,867
Surgery resulted in a safe, effective, and durable aesthetic
result in all patients, with a mean increase in the subcutaneous
thickness of the cheeks of 5.5 mm ( mm). After aSD 2.4
median of 17.5 months postsurgery, 4 patients who had fat
tissue harvested from a single site developed renewed fat ac-
cumulation at the harvest site. All 4 of these patients developed
simultaneous facial graft hypertrophy. For 3 patients, the graft
source had been the dorsocervical fat pad, and, for 1 patient,
the graft source had been subcutaneous abdominal fat tissue.
Patients described themselves as looking like “hamsters,” be-
cause of the prominence of their cheeks.
During the follow-up period, the 4 patients had their treat-
ment switched from stavudine to abacavir or tenofovir and
from a protease inhibitor to a nonnucleoside reverse-transcrip-
tase inhibitor or multiple nucleoside reverse-transcriptase in-
hibitors. None of the patients received steroids. The mean in-
crease in body weight was 2 kg.
Progressive facial lipohypertrophy of the cheeks after surgery
was documented by ultrasonography that was performed, in
all cases, by the same operator with a high-frequency (7.5 MHz)
transducer (3-GE Medical System; LOGIQ).
The mean increase in the subcutaneous thickness of the
cheeks from the time of surgery to the evaluation at month 24
was 14.6 mm ( mm; ) in the 4 patients. FigureSD 2.1 Pp .07
1 shows the increase in the subcutaneous thickness of the cheeks
in the 4 patients, compared with that of the overall cohort, and
also shows the morphological appearance of patient 1.
Discussion. The reasons for fat depletion and accumulation
in HIV-infected patients receiving antiretroviral therapy remain
unexplained. Microscopic examination of adipocytes in patients
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Figure 1. Top panel, Subcutaneous increase in cheek thickness, as measured by ultrasonography, in the 4 patients with facial lipohypertrophy (pt
1–4), as well as the mean thickness for the overall cohort (whiskers indicate SDs). Bottom panel, Photographs show lipohypertrophy of the dorsocervical
fat pad (upper row) and simultaneous hypertrophy of the facial fat graft (lower row). Written permission for use of the photographs was obtained
from the patient.
with lipoatrophy shows remodeling that involves a combination
of apoptosis, defective lipogenesis, and increased metabolic ac-
tivity in different areas [5]. Antiretroviral drugs may impair
lipid metabolism enzymes, which may result in hyperlipidemia,
insulin resistance, and apoptosis of adipocytes, because of the
great similarity between the low-density lipoprotein-receptor–
related protein and the cytoplasmic retinoic acid-binding pro-
tein type I. Several of the commonly used nucleoside analogues
inhibit mitochondrial enzymes (e.g., g-polymerase), producing
a progressive loss of mtDNA, with impairment of the oxidative
phosphorylation pathway.
Antiretroviral drugs may cause downregulation of TNF-a
homeostasis, altering transcriptional regulation, glucose levels,
fatty acid metabolism, and hormone receptor signaling. Hy-
pertrophy of the subcutaneous, denervated fat that was trans-
planted in the cheeks clearly suggests that the abnormal dis-
tribution of adipose tissue in HIV-infected patients cannot be
entirely explained as a selective neuropathy mediated via the
CNS but that some other circulating or humoral factor, as yet
unknown, should be taken into account to explain the path-
ogenesis of HIV-associated adipose redistribution syndrome
[6].
Our observations do not provide evidence for any patho-
genetic mechanism. The syndrome is unlikely to depend only
on paracrine factors, such as cytokine signals. In fact, paracrine
factors were present where the lipid alteration appeared, but
relapse occurred in a different area. Adipocyte receptors and
mitochondrial toxicity–related mechanisms could explain how
receptor expression, as well as mtDNA, could be transferred
from the harvest site to the graft site and remain sensitive to
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lipohypertrophy determinants. Another hypothesis is that li-
pohypertrophy of the cheeks may be the result of the expansion
of brown fat that is transferred with the intervention. Ultra-
structural observation suggests that dorsocervical fat consists
mainly of brown fat, and its expansion has been demonstrated
in areas undergoing white-fat atrophy, such as subcutaneous
abdominal tissue. Our data suggests that brown fat, which has
a higher mitochondria content, could be more prone to lipo-
hypertrophy and that it may be a mechanism that compensates
for fat atrophy.
The influence of genetic factors is suggested, as only a mi-
nority of the patients (21% of patients who received a graft
from the dorsocervical fat pad and 4% of patients who received
a graft from other sites) developed lipohypertrophy at the graft
site. A clinical implication is that, when autologous fat trans-
plantation is chosen for the treatment of facial lipoatrophy, the
preferred subcutaneous harvest site should be the abdomen or
pubis region.
Acknowledgments
We thank A. Grisotti, M. Callegari, M. De Lorenzi, I. Pecorari, and M.
Blini, for their active contribution in the surgery activities; G. Nardini and
B. Beghetto, for their assistance in the project; and G. Amorico, for per-
forming ultrasonography.
Potential conflicts of interest. All authors: no conflicts.
References
1. Lichtenstein K, Delaney KM, Armon C, et al. Incidence and risk factors
for lipoatrophy (abnormal fat loss) in ambulatory HIV-1–infected pa-
tients. J Aquir Immune Defic Syndr 2003; 32:48–56.
2. Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. A 48-
week, randomized, open-label comparison of three abacavir-based sub-
stitutions approaches in the management of dyslipidemia and peripheral
lipoatrophy. J Aquir Immune Defic Syndr 2003; 33:22–8.
3. Coleman SR. Structural fat graft: the ideal filler? Clinic Plastic Surg
2001; 28:111–9.
4. Guaraldi G, De Fazio D, Orlando G, et al. Autologous fat transfer for
treating facial wasting in HIV body fat redistribution syndrome [abstract
722]. In: Program and abstracts of the 10th Conference on Retroviruses
and Opportunistic Infections (Boston). 2003. Available at: http://
www.retroconference.org/2003/. Accessed 19 December 2004.
5. Lloreta J, DOmingo P, Pujol RM, et al. Ultrastructural feature of highly
active antiretroviral therapy–associated partial lipodystrophy. Virchows
Archives 2002; 441:599–604.
6. Fliers E, Sauerwein HP, Romijn JA, et al. HIV-associated adipose re-
distribution syndrome as a selective autonomic neuropathy. Lancet
2003; 362:1758–60.
 at U
niversitàdegli Studi di M
odenae Reggio Em
ilia on N
ovem
ber 8, 2012
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
